Please login to the form below

Not currently logged in
Email:
Password:

EMEA grants Jerini marketing application for angioedema

German pharmaceutical company Jerini has had its Marketing Authorisation Application granted by the European Medicines Evaluation Agency  for Icatibant in the treatment of hereditary angioedema

German pharmaceutical company Jerini has had its Marketing Authorisation Application (MAA) granted by the European Medicines Evaluation Agency (EMEA) for Icatibant in the treatment of hereditary angioedema (HAE).

The agency's Committee for Medicinal Products for Human Use (CHMP) has also granted Jerini accelerated assessment for the review of this submission, which shortens the regulatory review period from 210 to 150 calendar days and is granted to drug candidates addressing major public health interest and therapeutic innovation.

Hereditary angioedema (HAE) is a rare, potentially fatal genetic disorder typified by a deficiency or dysfunction of the plasma protein C1 Inhibitor, and characterised clinically by swelling of the extremities, face, trunk, abdominal viscera, and upper airway.

The start of Jerini's EMEA regulatory review period begins on August 15, 2007, and an opinion from the agency's committee could be received as early as first quarter 2008. EMEA approval provides marketing authorization in all 27 EU member states as well as Norway, Iceland, and Liechtenstein.

Jens Schneider-Mergener, CEO of Jerini, said of the acceptance: "This milestone along with our accelerated assessment status provides clarity for our regulatory timeline moving forward. Jerini is very confident that we can provide HAE patients with an exciting new treatment concept in the near future. Icatibant is the first-in-class bradykinin antagonist which, when approved, will enable this patient group to better manage their disease, thereby improving their quality of life."

16th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics